Functional Characterization of a Distinct Ryanodine Receptor Mutation in Human Malignant Hyperthermia-susceptible Muscle
Malignant hyperthermia is an inherited autosomal disorder of skeletal muscle in which certain volatile anesthetics and depolarizing muscle relaxants trigger an abnormally high release of Ca 2+ from the intracellular Ca 2+ store, the sarcoplasmic reticulum. In about 50% of cases, malignant hypertherm...
Gespeichert in:
Veröffentlicht in: | The Journal of biological chemistry 1997-02, Vol.272 (8), p.5256-5260 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Malignant hyperthermia is an inherited autosomal disorder of skeletal muscle in which certain volatile anesthetics and depolarizing
muscle relaxants trigger an abnormally high release of Ca 2+ from the intracellular Ca 2+ store, the sarcoplasmic reticulum. In about 50% of cases, malignant hyperthermia susceptibility is linked to the gene encoding
the skeletal muscle ryanodine receptor/Ca 2+ release channel (RYR1). To date, eight point mutations have been identified in human RYR1. Although these mutations are thought
to lead to an increased caffeine and halothane sensitivity in the contractile response of skeletal muscle, their functional
consequences have not been investigated on the molecular level. In the present study, we provide the first functional characterization
of a point mutation located in the central part of RYR1, Gly 2434 â Arg. Using high affinity [ 3 H]ryanodine binding as the experimental approach, we show that this mutation enhances the sensitivity of RYR1 to activating
concentrations of Ca 2+ and to the exogenous and diagnostically used ligands caffeine and 4-chloro- m -cresol. In parallel, the sensitivity to inhibiting concentrations of Ca 2+ and calmodulin was reduced, transferring the mutant Ca 2+ release channel into a hyperexcitable state. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.272.8.5256 |